These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 22915767)
1. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767 [TBL] [Abstract][Full Text] [Related]
2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762 [TBL] [Abstract][Full Text] [Related]
4. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. Lenčová-Popelová O; Jirkovský E; Mazurová Y; Lenčo J; Adamcová M; Šimůnek T; Geršl V; Štěrba M PLoS One; 2014; 9(5):e96055. PubMed ID: 24804796 [TBL] [Abstract][Full Text] [Related]
5. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693 [TBL] [Abstract][Full Text] [Related]
6. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284 [TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229 [TBL] [Abstract][Full Text] [Related]
8. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588 [TBL] [Abstract][Full Text] [Related]
9. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats. Gounder VK; Arumugam S; Arozal W; Thandavarayan RA; Pitchaimani V; Harima M; Suzuki K; Nomoto M; Watanabe K Int Immunopharmacol; 2014 Feb; 18(2):282-9. PubMed ID: 24291173 [TBL] [Abstract][Full Text] [Related]
10. Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice. Sahu BD; Kumar JM; Kuncha M; Borkar RM; Srinivas R; Sistla R Life Sci; 2016 Jan; 144():8-18. PubMed ID: 26606860 [TBL] [Abstract][Full Text] [Related]
11. New iron chelators in anthracycline-induced cardiotoxicity. Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820 [TBL] [Abstract][Full Text] [Related]
13. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. Adamcova M; Lencova-Popelova O; Jirkovsky E; Mazurova Y; Palicka V; Simko F; Gersl V; Sterba M Int J Cardiol; 2015 Dec; 201():358-67. PubMed ID: 26310978 [TBL] [Abstract][Full Text] [Related]
14. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. de Nigris F; Rienzo M; Schiano C; Fiorito C; Casamassimi A; Napoli C Eur J Cancer; 2008 Feb; 44(3):334-40. PubMed ID: 18194856 [TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y Toxicology; 2010; 274(1-3):18-26. PubMed ID: 20452391 [TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Vávrová A; Popelová O; Stěrba M; Jirkovský E; Hašková P; Mertlíková-Kaiserová H; Geršl V; Simůnek T Arch Toxicol; 2011 May; 85(5):525-35. PubMed ID: 21046361 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Marechal X; Montaigne D; Marciniak C; Marchetti P; Hassoun SM; Beauvillain JC; Lancel S; Neviere R Clin Sci (Lond); 2011 Nov; 121(9):405-13. PubMed ID: 21605084 [TBL] [Abstract][Full Text] [Related]
19. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Thompson KL; Rosenzweig BA; Zhang J; Knapton AD; Honchel R; Lipshultz SE; Retief J; Sistare FD; Herman EH Cancer Chemother Pharmacol; 2010 Jul; 66(2):303-14. PubMed ID: 19915844 [TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Jaenke RS; Deprez-DeCampeneere D; Trouet A Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]